Biofficient Successfully Launches "Match.com" for Biotech Industry at DIA 2013

July 2, 2013

Company News Release

Boston-Based Startup Debuts First-of-its-Kind Platform Automating RFP Process for Clinical Trial Sponsors and Service Providers

Boston-Based Startup Debuts First-of-its-Kind Platform Automating RFP Process for Clinical Trial Sponsors and Service Providers

Biofficient Inc. today announced the successful launch of its new platform to accelerate the outsourcing process for the biopharmaceutical drug development process. The company debuted the product to the biotech industry at last week’s annual DIA conference in Boston, MA.

Biofficient.com, the company’s website which hosts the platform, offers a streamlined solution to the arduous process of matching clinical trial sponsors’ specific needs with a comprehensive database of contract services provided by a global list of industry vendors. Completely secure and confidential, sponsors are able to create and send their RFPs to the vendors they select from a list generated by Biofficient’s adaptive matching algorithms.

On the other side of the process, Biofficient opens doors to new business for thousands of vendors that may otherwise not have been aware of valuable projects within their realm of expertise. By building out their free vendor profile on Biofficient’s easy-to-navigate site, qualified companies become a visible, viable contender for business in a highly competitive marketplace.

“We saw an opportunity to greatly improve the inefficiencies on both sides of the biopharmaceutical RFP process, and built out a solution that is beneficial to both the trial sponsors and contract service vendors. In a market that is increasingly relying on outsourced work,  a faster, simpler, more cost-efficient way of bringing both parties together and improving the quality of the entire experience as a whole is critical,” said Biofficient CEO Bret Siarkowski..

For more information about Biofficient, or to register for their platform, visit www.biofficient.com or call (888) 560-7007.

Related Content:

News